Supplementary

Table S1 DES and their characteristics

Characteristics	Orsiro*	Resolute integrity°	Resolute onyx°
Drug eluted	Sirolimus	Zotarolimus	Zotarolimus
Durability of polymer coating	Biodegradable	Durable	Durable
Distribution of polymer coating	Circumferential, asymmetrical	Circumferential, symmetrical	Circumferential, symmetrical
Platform material	Cobalt chromium	Cobalt chromium	Cobalt chromium with platinum-indium core
Polymer coating	Poly(L-lactide) acid (PLLA)	BioLinx polymer system	BioLinx polymer system
Polymer thickness	7.4 µm (abluminal) 3.5 µm (luminal)	5.6 µm (circumferential)	5.6 µm (circumferential)
Strut thickness	<3.5 mm stent: 60 µm; ≥3.5 mm stent: 80 µm	all stents: 91 µm	<4.0 mm stent: 81 µm; ≥4.5 mm stent: 91 µm

*, Biotronik, Bülach, Switzerland; °, Medtronic, Santa, California, USA. DES, drug-eluting stent.

Table S2 Subgroup-analysis assessing effect of different vessel sizes on 3-year outcome of ultrathin-strut BP-SES and thin-strut DP-ZES

Outcome	BP-SES (n=177)				DP-ZES (n=183)			
	Vessel <2.75 mm (n=110)	Vessel ≥2.75 mm (n=67)	HR (95% CI)	$P_{log\text{-}rank}$	Vessel <2.75 mm (n=90)	Vessel ≥2.75 mm (n=93)	HR (95% CI)	$P_{log\text{-}rank}$
TVF[†]	15 (14.0)	4 (6.0)	2.37 (0.79–7.15)	0.11	19 (21.4)	13 (14.4)	1.60 (0.79–3.24)	0.19
Cardiac death	5 (4.8)	2 (3.2)	1.52 (0.29–7.81)	0.62	4 (4.6)	5 (5.7)	0.83 (0.22–3.07)	0.77
Target vessel related MI	6 (5.6)	1 (1.6)	3.71 (0.45–30.84)	0.19	9 (10.3)	3 (3.5)	3.17 (0.86–11.72)	0.07
TVR	5 (4.8)	2 (3.2)	1.52 (0.29–7.81)	0.62	12 (13.9)	7 (8.2)	1.84 (0.72–4.66)	0.19
TLR	2 (1.9)	2 (3.2)	0.60 (0.09–4.28)	0.61	9 (10.3)	5 (5.7)	1.91 (0.64–5.69)	0.24
Target lesion failure[‡]	13 (12.1)	4 (6.0)	2.04 (0.67–6.26)	0.20	16 (18.0)	11 (12.2)	1.58 (0.73–3.39)	0.24
Probable or definite stent thrombosis	1 (1.0)	1 (1.6)	0.61 (0.04–9.79)	0.90	3 (3.5)	1 (1.1)	3.06 (0.32–29.44)	0.31
MACE[§]	21 (19.1)	7 (10.5)	1.88 (0.80–4.43)	0.14	22 (24.6)	15 (16.4)	1.59 (0.83–3.07)	0.16
All-cause death	12 (10.9)	5 (7.5)	1.44 (0.51–4.10)	0.49	10 (11.4)	8 (8.8)	1.27 (0.51–3.24)	0.60
MI	8 (7.5)	1 (1.6)	5.00 (0.63–40.04)	0.09	10 (11.4)	4 (4.6)	2.65 (0.83–8.45)	0.09

Data are n (%), unless otherwise indicated. [†], the composite endpoint of target vessel failure is a composite of cardiac death, target vessel related myocardial infarction, and clinically indicated target vessel revascularization; [‡], target lesion failure is a composite of cardiac death, target vessel related myocardial infarction, and clinically indicated target lesion revascularization; [§], major adverse cardiac events is a composite of all-cause death, any myocardial infarction, emergent coronary artery bypass surgery, and clinically indicated target lesion revascularization. BP-SES, biodegradable polymer sirolimus-eluting stents; DP-ZES, durable polymer zotarolimus-eluting stents; TVF, target vessel failure; TVR, target vessel revascularization; TLR, target lesion revascularization; MACE, major adverse cardiac events; MI, myocardial infarction; HR, hazard ratio; CI, confidence interval.

https://dx.doi.org/10.21037/cdt-22-584

Table S3 P values for interaction between small vessel target lesion and type of DES

Variables	P value
TVF[†]	0.56
TVR	0.84
TLR	0.31

[†], the composite endpoint of target vessel failure is a composite of cardiac death, target vessel related myocardial infarction, and clinically indicated target vessel revascularization. DES, drug-eluting stent; TVF, target vessel failure; TVR, target vessel revascularization; TLR, target lesion revascularization.

Table S4 Subgroup-analysis in small vessel disease assessing effect of ultrathin-strut BP-SES versus thin-strut DP-ZES on 3-year outcome

Outcome	Vessel <2.75 mm (n=200)				Vessel ≥2.75 mm (n=160)			
	BP-SES (n=110)	DP-ZES (n=90)	HR (95% CI)	$P_{log\text{-}rank}$	BP-SES (n=67)	DP-ZES (n=93)	HR (95% CI)	$P_{log\text{-}rank}$
TVF[†]	15 (14.0)	19 (21.5)	0.62 (0.31-1.21)	0.16	4 (6.0)	13 (14.4)	0.41 (0.13-1.27)	0.11
Cardiac death	5 (4.7)	4 (4.6)	1.00 (0.27-3.74)	1.00	2 (3.2)	5 (5.7)	0.55 (0.11-2.84)	0.47
Target vessel related MI	6 (5.6)	9 (10.3)	0.54 (0.19-1.52)	0.23	1 (1.6)	3 (3.5)	0.45 (0.05-4.36)	0.48
TVR	6 (5.6)	12 (13.9)	0.32 (0.11-0.91)	0.024*	2 (3.2)	7 (8.2)	0.39 (0.08-1.85)	0.22
TLR	2 (1.9)	9 (10.3)	0.17 (0.04-0.80)	0.011*	2 (3.2)	5 (5.7)	0.55 (0.11-2.82)	0.46
Target lesion failure[‡]	13 (12.1)	16 (18.0)	0.64 (0.31-1.33)	0.23	4 (6.0)	11 (12.2)	0.49 (0.16-1.55)	0.22
Probable or definite stent thrombosis	1 (1.0)	3 (3.5)	0.27 (0.03-2.58)	0.22	1 (1.6)	1 (1.1)	1.38 (0.09-22.02)	0.82
MACE[§]	21 (19.1)	22 (24.6)	0.74 (0.41-1.35)	0.33	7 (10.5)	15 (16.4)	0.63 (0.26-1.55)	0.31
All-cause death	12 (10.9)	10 (11.4)	0.96 (0.42-2.23)	0.93	5 (7.5)	8 (8.8)	0.86 (0.28-2.64)	0.80
MI	8 (7.5)	10 (11.4)	0.65 (0.26-1.65)	0.36	1 (1.6)	4 (4.6)	0.34 (0.04-3.06)	0.31

Data are n (%), unless otherwise indicated. [†], the composite endpoint of target vessel failure is a composite of cardiac death, target vessel related myocardial infarction, and clinically indicated target vessel revascularization; [‡], target lesion failure is a composite of cardiac death, target vessel related myocardial infarction, and clinically indicated target lesion revascularization; [§], major adverse cardiac events is a composite of all-cause death, any myocardial infarction, emergent coronary artery bypass surgery, and clinically indicated target lesion revascularization; *, statistically significant. BP-SES, biodegradable polymer sirolimus-eluting stents; DP-ZES, durable polymer zotarolimus-eluting stents; TVF, target vessel failure; TVR, target vessel revascularization; TLR, target lesion revascularization; MACE, major adverse cardiac events; MI, myocardial infarction; HR, hazard ratio; CI, confidence interval.

https://dx.doi.org/10.21037/cdt-22-584